I-Corps: Three Dimensional Bio-Printing of Human Tissues

这个i-Corps项目的更广泛的影响/商业潜力是增加成本效益高的自动化3D生物打印平台的可用性，能够原位重建生物组织。现有的生物打印技术是有限的，只有拥有大量资源的机构才能使用，因此限制了它可以为学术和非学术部门带来的潜力。在工业中，由于药物测试的不准确和使用动物模型时翻译差距的错误，许多后期试验可能会失败。作为另一种选择，在进行动物模型测试之前，对3D打印的人体组织模型进行测试可以降低成本，这是一个有价值的中间步骤。其次，制药公司的3D生物打印应用将增加药物筛选的吞吐量。第三，学术界的研究人员可以在3D生物材料工程方面取得进一步进展。第四，随着教育部门走向下一代科学标准课程，生物打印机作为课堂实践学习的创新工具具有巨大的潜力。教育工作者可以将3D生物打印作为一种强大的教学工具来培训和支持下一代科学家从事他们的研究。最终，该项目旨在为研究人员和学生创造积极的影响，并改善他们在世界各地获得技术的机会。这个i-Corps项目基于一项核心技术，允许研究人员打印各种组织结构。这种生物打印机能够使用人类成纤维细胞和角质形成细胞重建有活力的皮肤结构。这个项目？S最低生存产品(MVP)是一台生物打印机，采用了三种不同的技术，采用了多模块系统。该产品使用的技术支持在构建3D高保真支架期间按需定制生物材料，并可精确放置精确到微米级的细胞。这些模块结合在一起，创造了一款用途广泛的多功能产品。这一进展将提高生物打印技术的可及性，并将进一步推动组织工程的进步。这一奖项反映了NSF的法定使命，并通过使用基金会的智力优势和更广泛的影响审查标准进行评估，被认为值得支持。

The broader impact/commercial potential of this I-Corps project is to increase the availability of cost-effective automated 3D bioprinting platforms capable of reconstructing biological tissue in situ. Existing bioprinting technology is limited and only available to institutions with vast amounts of resources, therefore limiting the potential it can bring to both academic and non-academic sectors. In industry, industry, many late stage trials can fail due to inaccurate drug testing and errors in the translational gap when using animal models. As an alternative, testing on 3D printed human tissue models could reduce costs as a valuable intermediate step before proceeding to animal model testing. Second, 3D bioprinting applications in pharmaceutical companies will increase throughput in drug screening. Third, researchers in academia can further advances in 3D biomaterial engineering. Fourth, with the education sector moving towards a Next Generation Science Standards curriculum, bioprinters have immense potential as an innovative tool for hands-on learning in the classroom. Educators can utilize 3D bioprinting as a powerful teaching tool to train and empower the next generation of scientists in pursuing their research. Ultimately, this project aims to create a positive impact and improve technological access worldwide for researchers and students alike.This I-Corps project is based on a core technology that allows researchers to print various tissue constructs. This bioprinter is able to reconstruct a viable skin construct using human fibroblasts and keratinocytes. The project?s minimum viable product (MVP) is a bioprinter with a multi-modular system using three different technologies. The technologies used in this product enable on-demand biomaterial customization during the construction of a 3D high-fidelity scaffold and precision placement of cells down to the micron level. Together, the combination of these modules creates a versatile product that has broad applications. This development will improve accessibility of the bioprinting technology and will further advancements in tissue engineering.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.